Abiomed Stock Price Target and Analyst Ratings (NASDAQ:ABMD)

Analyst Price Target for ABMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$238.25

▼ -27.67% Downside Potential

This price target is based on 6 analysts offering 12 month price targets for Abiomed in the last 3 months. The average price target is $238.25, with a high forecast of $320.00 and a low forecast of $155.00. The average price target represents a -27.67% upside from the last price of $329.38.

Hold

The current consensus among 6 polled investment analysts is to hold stock in Abiomed. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

7/24/2019

0 strong buy ratings
2 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

10/22/2019

0 strong buy ratings
2 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/20/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/19/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

7/18/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/16/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

12/15/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

1/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/21/2020	SVB Leerink	Boost Price Target	Positive ➝ Market Perform	$280.00 ➝ $320.00	High	i
12/15/2020	Morgan Stanley	Boost Price Target	Underweight	$217.00 ➝ $238.00	Medium	i
10/12/2020	SVB Leerink	Lower Price Target	Market Perform	$335.00 ➝ $280.00	Medium	i Rating by D. Antalffy at SVB Leerink LLC
8/7/2020	Morgan Stanley	Boost Price Target	Underweight	$152.00 ➝ $217.00	Medium	i Rating by David Lewis at Morgan Stanley
8/7/2020	SVB Leerink	Boost Price Target	Market Perform	$280.00 ➝ $335.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
7/13/2020	OTR Global	Upgrade	Positive		High	i
5/28/2020	SVB Leerink	Boost Price Target	Market Perform	$195.00 ➝ $225.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
5/27/2020	BTIG Research	Downgrade	Hold		High	i Rating by Marie Thibault at BTIG Research
5/1/2020	Morgan Stanley	Boost Price Target	Underweight	$149.00 ➝ $152.00	Medium	i Rating by David Lewis at Morgan Stanley
4/27/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$220.00 ➝ $175.00	High	i Rating by Danielle Antalffy at SVB Leerink LLC
3/27/2020	Morgan Stanley	Lower Price Target	Underweight	$165.00 ➝ $149.00	Low	i Rating by David Lewis at Morgan Stanley
3/23/2020	Piper Sandler	Reiterated Rating	Buy	$240.00	High	i Rating by Matthew O'Brien at Piper Sandler
3/23/2020	Stephens	Lower Price Target	Overweight	$240.00 ➝ $155.00	High	i
2/11/2020	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$198.00 ➝ $165.00	High	i
2/6/2020	BTIG Research	Initiated Coverage	Hold		High	i
12/17/2019	Morgan Stanley	Lower Price Target	Equal Weight	$215.00 ➝ $198.00	Low	i
11/1/2019	SVB Leerink	Boost Price Target	Outperform	$195.00 ➝ $240.00	High	i
10/29/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		High	i
9/30/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Margaret Kaczor at William Blair
8/2/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Margaret Kaczor at William Blair
8/2/2019	Guggenheim	Downgrade	Buy ➝ Neutral		Medium	i
8/1/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$325.00 ➝ $215.00	Medium	i
8/1/2019	BTIG Research	Downgrade	Buy ➝ Neutral		High	i
5/7/2019	BTIG Research	Reiterated Rating	Buy		Low	i
5/3/2019	SunTrust Banks	Reiterated Rating	Buy	$340.00	Low	i
1/22/2019	BTIG Research	Reiterated Rating	Buy	$400.00	Low	i
1/2/2019	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$496.00 ➝ $461.00	High	i
11/7/2018	Morgan Stanley	Upgrade	Equal ➝ Equal Weight	$396.00 ➝ $496.00	Medium	i
11/2/2018	BTIG Research	Upgrade	Neutral ➝ Buy	$450.00	Low	i
10/11/2018	Morgan Stanley	Boost Price Target	Equal Weight	$370.00 ➝ $396.00	High	i
6/22/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$360.00 ➝ $480.00	High	i
5/29/2018	Jefferies Financial Group	Boost Price Target	Buy	$460.00	Medium	i
5/3/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$360.00	High	i
5/1/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$259.00 ➝ $320.00	Medium	i
4/4/2018	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$332.00	Medium	i Rating by Issac Ro at The Goldman Sachs Group, Inc.
2/16/2018	SunTrust Banks	Reiterated Rating	Buy	$370.00	N/A	i
2/4/2018	BTIG Research	Reiterated Rating	Hold		High	i
2/2/2018	SVB Leerink	Boost Price Target	Outperform	$300.00	Low	i
2/2/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$204.00 ➝ $259.00	Low	i
2/2/2018	Guggenheim	Reiterated Rating	Buy	$280.00	Medium	i
2/1/2018	Jefferies Financial Group	Reiterated Rating	Buy	$300.00	Medium	i
2/1/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Positive	$220.00 ➝ $300.00	Medium	i
1/19/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$200.00 ➝ $265.00	Low	i
1/12/2018	Jefferies Financial Group	Boost Price Target	Buy	$250.00	Medium	i
1/4/2018	Piper Jaffray Companies	Reiterated Rating	Buy		High	i
12/21/2017	Jefferies Financial Group	Boost Price Target	Buy	$208.00 ➝ $220.00	Medium	i
11/1/2017	SunTrust Banks	Reiterated Rating	Buy	$195.00	N/A	i
10/29/2017	BTIG Research	Reiterated Rating	Hold		N/A	i
10/26/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$200.00	N/A	i
10/16/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A	i
10/12/2017	SVB Leerink	Reiterated Rating	Outperform	$180.00 ➝ $200.00	N/A	i
9/29/2017	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$195.00	High	i
9/29/2017	Jefferies Financial Group	Boost Price Target	Buy	$175.00 ➝ $208.00	High	i
8/29/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$160.00	Low	i
8/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$175.00	Low	i
8/4/2017	Jefferies Financial Group	Boost Price Target	Buy	$165.00 ➝ $175.00	Low	i
7/27/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$145.00 ➝ $160.00	Medium	i
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$135.00 ➝ $140.00	Low	i
7/4/2017	Piper Jaffray Companies	Set Price Target		$145.00	Low	i
6/8/2017	William Blair	Reiterated Rating	Outperform ➝ Outperform		Low	i Rating by M. Kaczor at William Blair
4/6/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$145.00	Medium	i
3/30/2017	SVB Leerink	Boost Price Target	Outperform	$140.00 ➝ $150.00	Low	i
1/8/2017	BTIG Research	Reiterated Rating	Buy	$170.00	N/A	i
12/6/2016	Guggenheim	Initiated Coverage	Buy	$150.00	N/A	i
9/28/2016	SVB Leerink	Reiterated Rating	Outperform	$125.00	N/A	i Rating by Danielle Antalffy at SVB Leerink LLC
8/9/2016	Jefferies Financial Group	Boost Price Target	Buy	$130.00 ➝ $145.00	N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
7/29/2016	Jefferies Financial Group	Boost Price Target	Buy	$125.00 ➝ $130.00	N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
6/10/2016	Jefferies Financial Group	Reiterated Rating	Buy	$125.00	N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/5/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Danielle Antalffy at SVB Leerink LLC
5/4/2016	SVB Leerink	Reiterated Rating	Outperform	$120.00 ➝ $125.00	N/A	i Rating by Danielle Antalffy at SVB Leerink LLC
4/17/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Danielle Antalffy at SVB Leerink LLC
4/10/2016	Benchmark	Reiterated Rating	Buy	$145.00	N/A	i
4/9/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Raj Denhoy at Jefferies Financial Group Inc.
4/8/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i
3/22/2016	Jefferies Financial Group	Reiterated Rating	Buy	$125.00	N/A	i
2/5/2016	Piper Jaffray Companies	Reiterated Rating	Hold	$75.00 ➝ $90.00	N/A	i Rating by Brooks West at Piper Jaffray Companies
2/5/2016	BTIG Research	Reiterated Rating	Buy	$110.00	N/A	i Rating by Sean Lavin at BTIG Research
2/4/2016	Benchmark	Boost Price Target	Buy	$133.00 ➝ $145.00	N/A	i

(Data available from 1/15/2016 forward)

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Today's Range

Now: $329.38

$321.43

$329.85

50 Day Range

MA: $294.61

$258.45

$324.67

52 Week Range

Now: $329.38

$119.01

$330.80

Volume

12,219 shs

Average Volume

322,786 shs

Market Capitalization

$14.88 billion

P/E Ratio

72.39

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Abiomed?

The following Wall Street sell-side analysts have issued research reports on Abiomed in the last twelve months: BTIG Research, Morgan Stanley, OTR Global, Piper Sandler, Stephens, SVB Leerink LLC, and Zacks Investment Research.

What is the current price target for Abiomed?

4 Wall Street analysts have set twelve-month price targets for Abiomed in the last year. Their average twelve-month price target is $238.25, suggesting a possible downside of 25.2%. SVB Leerink LLC has the highest price target set, predicting ABMD will reach $320.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $155.00 for Abiomed in the next year.

What is the current consensus analyst rating for Abiomed?

Abiomed currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABMD, but not buy more shares or sell existing shares.

What other companies compete with Abiomed?

Other companies that are similar to Abiomed include Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, Becton, Dickinson and, Edwards Lifesciences, Boston Scientific, IDEXX Laboratories, Baxter International, DexCom, ResMed, Hologic, Insulet, Teleflex and STERIS.

How do I contact Abiomed's investor relations team?

Abiomed's physical mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider's listed phone number is 978-646-1400 and its investor relations email address is ir@abiomed.com. The official website for Abiomed is www.abiomed.com.

NASDAQ:ABMD - Abiomed Stock Price Target and Predictions

Analyst Price Target for ABMD

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Abiomed?

What is the current price target for Abiomed?

What is the current consensus analyst rating for Abiomed?

What other companies compete with Abiomed?

How do I contact Abiomed's investor relations team?